Clinical Trials Logo

Mucopolysaccharidosis III-A clinical trials

View clinical trials related to Mucopolysaccharidosis III-A.

Filter by:
  • None
  • Page 1

NCT ID: NCT06095388 Recruiting - Clinical trials for Mucopolysaccharidosis III-A

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

Start date: October 4, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.

NCT ID: NCT05523206 Recruiting - Clinical trials for Mucopolysaccharidosis III-A

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)

Start date: September 27, 2022
Phase:
Study type: Observational

This protocol is a decentralized, single cohort, natural history and biomarker study enrolling up to 20 participants with MPS IIIA (Sanfilippo syndrome). At least 10 participants (~50%) must be less than four years old at the time of the Parent/LAR consent. The study will have a screening process and 7 study visits, e.g. home visits, that will consist of serum collection and completion of a remote assessment of the Vineland Adaptive Behavior Scales 3rd Edition (Vineland-3) MPS IIIA remains a devastating disease with a high unmet medical need. There is currently a limited number of available data to adequately characterize the progression of the disease. Analysis of blood biospecimens and adaptive behavior in this study will help researchers better understand the clinical progression of MPS IIIA. A better understanding of disease progression may assist in developing novel therapies for rare genetic disorders.

NCT ID: NCT04360265 Enrolling by invitation - Clinical trials for Mucopolysaccharidosis III-A

A Long-term Follow-up Study of Patients With MPS IIIA Treated With ABO-102

Start date: September 28, 2020
Phase: Phase 3
Study type: Interventional

The main objective of this study is to evaluate the long-term safety and tolerability of ABO-102 in participants with MPS IIIA.